Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3.37M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
373K
-
Shares change
-
-8.68K
-
Total reported value, excl. options
-
$932K
-
Value change
-
-$29.3K
-
Number of buys
-
2
-
Number of sells
-
-3
-
Price
-
$2.50
Significant Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q1 2025
19 filings reported holding CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value as of Q1 2025.
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 373K shares
of 3.37M outstanding shares and own 11.09% of the company stock.
Largest 10 shareholders include TYNDALL CAPITAL PARTNERS L P (165K shares), Siren, L.L.C. (116K shares), GEODE CAPITAL MANAGEMENT, LLC (31.6K shares), VANGUARD GROUP INC (23.5K shares), BlackRock, Inc. (16.8K shares), UBS Group AG (13K shares), FMR LLC (4.94K shares), Tower Research Capital LLC (TRC) (1.05K shares), MORGAN STANLEY (649 shares), and GROUP ONE TRADING LLC (540 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.